 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced that a manuscript describing its budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv link. These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented 